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ABSTRACT 
Malignant ascites is a widespread impediment of advanced cancer but to 20% of all cases of malignant ascites have unknown primary tumours. With the 
exception of ovarian cancer, the response of the ascites to treatment of the tumor is unsatisfactory and treatment related morbidity is common. The intent of 
most treatments for malignant ascites should be palliative with diuretics paracentesis were the common approach. A 53 years old, male patients who was 
admitted with history of abdominal distention for past 3 month associated with altered bowel habit and mucus per rectum and significant loss weight. Patients 
was diagnosed as malignant ascites with multicentric hepatoma with abdominal lymphodenopathy, lung, liver and vertebral body metastasis and left portal 
vein thrombosis. Patient was managed with temporary external paracentesis (pigtail catheter) and oral furosemide 40 mg daily and spironolactone 100 mg 
daily. Although abdominal paracentesis, diuretics and peritoneovenous shunting are commonly used procedures in management of malignant ascites, there are 
no randomized controlled trials evaluating the efficacy and safety of these therapies. 
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INTRODUCTION 
Malignant ascites is defined by the National Cancer Institute 
as a condition in which fluid containing cancer cells collects 
in  the  abdomen.  This  can  occur  by  direct  invasion  of  the 
peritoneum, such as in peritoneal carcinomatosis, or it can 
occur secondarily from the local biologic effect of tumors or 
vena  caval  compression.  Approximately,  60%  of  patients 
with malignant ascites present with symptoms, which include 
abdominal  swelling  (55%),  abdominal  pain  (53%),  nausea 
(37%), anorexia (36%), vomiting (25%), and fatigue (17%).
1 
Cancer accounts for approximately 10% of all cases of ascites 
and commonly occurs in ovarian, endometrial, breast, colon, 
gastric and pancreatic carcinomas. Below 15% of all patients 
with gastrointestinal cancer develop ascites at some stage of 
their disease  whereas up to 20% of all cases  of malignant 
ascites have unknown primary tumours.
2 With the exception 
of ovarian cancer, the response of the ascites to treatment of 
the tumor is unsatisfactory and treatment re lated morbidity is 
common. Thus, the intent of most treatments for malignant 
ascites  should  be  palliative.  Other  than  treatment  of  the 
underlying cancer, there are no generally accepted evidence 
based guidelines for the prevention or reduction of ascites. 
Approaches have included sodium-restricted diets, diuretics, 
serial  paracenteses,  peritoneal  shunting  and  chemotherapy, 
both systemic and intraperitoneal.
3 We discuss the function  
of  diuretic  therapy  as  one  of  many  approaches  used  to  
control  this  obstacle. 
Case presentation 
A 53 years old, Malay male patient was admitted to Hospital 
Universiti Sains Malaysia (HUSM) with history of abdominal 
distention  for  past  3  month  associated  with  altered  bowel 
habit  and  mucus  per  rectum.  Patient  also  complained  of 
irregular  backpain,  low  of  appetite  and  loss  of  3  kg  body 
weight in 2 months. Patients had history of diabetes mellitus 
and currently on oral hypoglycemic agents.  The patient was 
found  to  have  defined  mass  at  right  iliac  fossa  and  no 
palpable  lymphodenopathy.  Colonoscopy  showed  external 
compression 10-20cm with erythematous lesion at rectal area. 
The peritoneal fluid was chylous and cytology found to be 
positive for adenocarcinoma. The computerized tomographic 
(CT)  scan  of  the  abdomen  revealed  multicentric  hepatoma 
with abdominal lymphodenopathy, lung, liver and vertebral 
body metastasis and left portal vein thrombosis. The patient 
was  undergone  peritoneal  tapping  and  temporary  external 
paracentesis  (pigtail  catheter)  and  currently  was  managed 
with oral furosemide 40 mg daily and spironolactone 100 mg 
daily.  Furthermore,  the  patients  also  managed  with  other 
medication in the ward such as: Syrup Lactulose 15ml, oral 
gliclazide 160mg daily, intravenous pantoprazole 40mg twice 
daily, intravenous metoclopramide 10mg when needed, oral 
cloxacilin 500mg four time daily, subcutaneous fondaparinux 
5mg  daily,  intravenous  cefoperazone  1g  twice  daily, 
intravenous  metronidazole  500mg  thrice  daily.  Patient  was 
undergone  1.5L/day  fluid  drainage  by  paracentesis 
managements  on  alternate  day.  Patient  was  discharge  with 
marked  response  in  bowel  movement  and  resolution  of 
ascites with diuretics and paracentesis treatments. No adverse 
effects  of  diuretics  occurred  and  the  blood  pressure, 
electrolytes, blood urea nitrogen, and albumin all remained 
normal. 
DISCUSSION 
Ascites  results  either  from  overproduction  of  fluid  from 
visceral capillaries in the peritoneum, impaired drainage by 
visceral or diaphragmatic lymphatics, or both.
2 Compared to 
ascites caused by cirrhosis, malignant ascites usually contains 
more  white  blood  cells  and  a  higher  level  of  lactate 
dehydrogenase.  Malignant  cells  are  more  often  found  in 
exudative  ascites  and  positive  cytology  is  demonstrated  in 
almost  50%  of  the  cases.
4  Endothelial  permeability  is 
increased in exudative ascites resulting in increased protein 
concentration in the fluid. Chylous ascites may result from 
extravasation  of  chyle  into  the  peritoneal  cavity  due  to 
lymphatic  obstruction  by  tumor.  The  prognosis  for  these 
patients depends on the treatment of the underlying disease.
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Once  the  diagnosis  of  malignant  ascites  is  established, 
treatment is largely palliative and aimed at symptom control 
however  therapeutic  success  is  often  limited.  There  is  no 
standardized protocol exists for treatment of cancer patients 
with rapidly reaccumulating ascites and approaches such as 
diuretics,  paracentesis  and  peritoneovenous  shunts  are 
implemented empirically.
2 
Diuretic  use  in  managing  malignant  ascites  is  inconsistent 
among physicians and no randomized trial was done to assess 
the efficacy of diuretic therapy in malignant ascites. The use 
of  aldosterone  antagonists,  such as  spironolactone  100-200 
mg daily, either alone or in combination with a loop diuretic 
(e.g.,  furosemide  40-80  mg  daily)  may  be  able  to  provide 
adequate control. 
5 studies were evaluated with a total of 113 
patients  with  a  variety  of  tumor  types,  and  found  that 
approximately  43%  of  patients  attained  ascites  symptom 
relief with diuretic management.
 5 
Recommendation  was  to  use  spironolactone,  starting  at  a 
dose of 150 mg per day, and increasing the dose every few 
days until a response is achieved, or clinical features prevent 
further increase. During this titration, it would be important 
to  monitor  the  urea  and  electrolytes  regularly,  and  if 
hyperkalaemia were to develop, furosemide could substitute 
for additional spironolactone. Once a response is achieved, it 
may be possible to reduce the dose of diuretic required for 
maintenance therapy.
1 
Paracentesis is indicated for those patients with ascites who 
have  symptoms  of  abdominal  pressure  such  as  nausea, 
vomiting,  pain,  dyspnoea  or  orthopnoea.  Paracentesis 
produces  temporary  relief  of  these  symptoms  in 
approximately  90%  of  patients.
4  As  the  average  life 
expectancy for patients with malignant ascites is less than 6 
months
7,  repeated  paracentesis  often  plays  an  important 
palliative role in those patients whom chemotherapy is fail. 
The study recommended that the removal of at least 0.5 L is 
usually  necessary  to  provide  some  degree  of  symptomatic 
relief.
6 Reports have suggested that rapid paracentesis can be 
safely  performed,  with  up  to  4  liter  within  1–2  hours, 
providing that the  intravascular  volume  is  maintained  with 
intravenous albumin and dextrose 5% in order to avoid renal 
and electrolyte disturbance.
4 
CONCLUSION: 
The management of malignant ascites is unclear and there are 
no  validated  guidelines  for  the  prevention  or  reduction  of 
fluid re-accumulation. Abdominal paracentesis, diuretics and 
peritoneovenous shunting are commonly used procedures in 
management  of  malignant  ascites,  but  need  to  explore  the 
efficacy  and  safety  of  these  therapies.  Therapeutic 
paracentesis  should  be  done  if  ascites  is  associated  with 
respiratory distress or if symptomatic ascites is resistant to 
diuretics. However, paracentesis was superior to diuretics if 
the benefit outweights the risk.  
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